Loading...

Cytokinetics, Incorporated

CYTKNASDAQ
Healthcare
Biotechnology
$33.04
$0.00(0.00%)

Cytokinetics, Incorporated (CYTK) Company Profile & Overview

Explore Cytokinetics, Incorporated’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Cytokinetics, Incorporated (CYTK) Company Profile & Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

SectorHealthcare
IndustryBiotechnology
CEORobert I. Blum

Contact Information

650 624 3000
350 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

498 Employees
IPO DateApr 30, 2004
CountryUS
Actively Trading

Frequently Asked Questions

;